Quick Answer
Vicapsys Life Sciences, Inc. reported Stockholders Equity of -$1.93 million for fiscal year 2023.
Vicapsys Life Sciences, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2023 | -$1.93M | -102.9% |
| 2022 | -$950.8K | -681.6% |
| 2021 | -$121.7K | +72.9% |
| 2020 | -$449.1K | -248.7% |
| 2019 | $302.0K | +219.0% |
| 2018 | -$253.7K | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2024 | -$2.65M | -98.3% | -8.2% |
| June 30, 2024 | -$2.45M | -123.7% | -8.4% |
| March 31, 2024 | -$2.26M | -97.6% | -17.0% |
| December 31, 2023 | -$1.93M | -102.9% | -44.6% |
| September 30, 2023 | -$1.33M | -156.4% | -22.0% |
| June 30, 2023 | -$1.09M | -134.4% | +4.2% |
| March 31, 2023 | -$1.14M | -296.8% | -20.0% |
| December 31, 2022 | -$950.8K | -681.6% | -82.7% |
- Vicapsys Life Sciences, Inc. showed a decrease of -102.9% in Stockholders Equity compared to the prior fiscal year.
- Over the 2018–2023 period, Vicapsys Life Sciences, Inc.’s stockholders equity has declined by 660.3% (from -$253.7 thousand to -$1.93 million).
- The most recent figure is from Vicapsys Life Sciences, Inc.’s fiscal year 2023 report (Form 10-K), filed with the SEC on October 21, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: